Payment overview · 2025
General Payments
$192.31
5 reported records · 4 companies
Healthcare provider profile · identity verified
Jorge Luis Santander, MD
Allopathic & Osteopathic Physicians|Family Medicine · MIAMI, FL · NPI 1467499285
Verified facts
What the public records show
CMS Open Payments records show Jorge Luis Santander, MD received $192.31 in general payments during 2025 across 5 reported records.
Exact Sciences Corporation accounted for 59.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $114.13 | 59.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.07 | 19.8% | 2 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $25.68 | 13.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.43 | 7.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $192.31 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $114.13 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $38.07 | 2 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $25.68 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $25.68 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.43 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
67 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 229 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 200 | 60 |
| Atorvastatin Calcium | Atorvastatin Calcium | 198 | 68 |
| Lorazepam | Lorazepam | 195 | 44 |
| Famotidine | Famotidine | 190 | 51 |
| Metformin Hcl | Metformin Hcl | 172 | 55 |
| Losartan Potassium | Losartan Potassium | 167 | 51 |
| Ibuprofen | Ibuprofen | 160 | 64 |
| Gabapentin | Gabapentin | 156 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 156 | 40 |
| Azithromycin | Azithromycin | 147 | 91 |
| Diclofenac Sodium | Diclofenac Sodium | 141 | 59 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 140 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 120 | 44 |
| Montelukast Sodium | Montelukast Sodium | 114 | 29 |
| Alendronate Sodium | Alendronate Sodium | 109 | 33 |
| Alprazolam | Alprazolam | 107 | 26 |
| Furosemide | Furosemide | 94 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 25 |
| Ketoconazole | Ketoconazole | 92 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 89 | 25 |
| Ammonium Lactate | Ammonium Lactate | 86 | 30 |
| Temazepam | Temazepam | 86 | 14 |
| Simvastatin | Simvastatin | 83 | 30 |
| Valsartan | Valsartan | 81 | 16 |
| Trazodone Hcl | Trazodone Hcl | 78 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 16 |
| Folic Acid | Folic Acid | 72 | 31 |
| Ozempic | Semaglutide | 72 | suppressed |
| Lisinopril | Lisinopril | 71 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 27 |
| Farxiga | Dapagliflozin Propanediol | 67 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 19 |
| Clonazepam | Clonazepam | 62 | 15 |
| Meloxicam | Meloxicam | 61 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 29 |
| Carvedilol | Carvedilol | 59 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | 16 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 58 | 39 |
| Potassium Chloride | Potassium Chloride | 57 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 51 | 14 |
| Diclofenac Sodium Er | Diclofenac Sodium | 50 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 14 |
| Latanoprost | Latanoprost | 47 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 44 | 20 |
| Donepezil Hcl | Donepezil Hcl | 44 | 11 |
| Amoxicillin | Amoxicillin | 43 | 32 |
| Hydrocortisone | Hydrocortisone | 42 | 15 |
| Glipizide | Glipizide | 41 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 40 | suppressed |
| Allopurinol | Allopurinol | 39 | 14 |
| Januvia | Sitagliptin Phosphate | 38 | 13 |
| Jardiance | Empagliflozin | 38 | suppressed |
| Lactulose | Lactulose | 38 | 15 |
| Enalapril Maleate | Enalapril Maleate | 37 | suppressed |
| Mupirocin | Mupirocin | 37 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 13 |
| Meclizine Hcl | Meclizine Hcl | 35 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 16 |
| Eliquis | Apixaban | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 11 |
| Cephalexin | Cephalexin | 29 | 23 |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | 12 |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | 12 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Ssd | Silver Sulfadiazine | 26 | 18 |
| Baclofen | Baclofen | 24 | 11 |
| Glimepiride | Glimepiride | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 22 | 16 |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Pentoxifylline | Pentoxifylline | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 21 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | 13 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 14 |
| Atenolol | Atenolol | 18 | suppressed |
| Humalog | Insulin Lispro | 18 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Pregabalin | Pregabalin | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Restasis Multidose | Cyclosporine | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Invokamet | Canagliflozin/Metformin Hcl | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $192.31 · 5 records | Exact Sciences Corporation | FARXIGA, Natroba, QULIPTA, Spinosad, The Cologuard Plus Collection Kit, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error